New insulin device for better dose control from Novo Nordisk

InnoLet, a prefilled disposable doser developed and marketed by Novo Nordisk, is designed to replace the vial and syringe method of insulin delivery used by most Americans with diabetes.

The device features a number of design innovations. Its dosing dial, which resembles a kitchen timer, has large, easy-to-read numbers and clicks audibly at each dosing level. The large grip and ergonomic design of InnoLet make it easy and comfortable to hold, provide injection stability and control over injection depth, and decrease tremor or movement at the needle tip. The insulin reservoir can be viewed easily; one-unit increments allow accurate, fine-tuned dosing, and a reversible dose mechanism allows patients to correct a misdialled dose. In addition, the individual cannot dial a dose larger than the insulin remaining in the reservoir, thereby preventing under-dosing.

'In developing InnoLet, we worked closely with people who have diabetes to determine their most important issues and needs,' said Martin Soeters, president of Novo Nordisk Pharmaceuticals. 'Concern over inaccurate dosing and ease of use are of considerable importance to people with diabetes. InnoLet offers accuracy, dose consistency and ease of use, as well as quick and discreet injection, in contrast to the age-old vial and syringe method.'

The company believes that the device will enable people with type 2 diabetes to self-manage their disease better and give health care providers a time-saving and simpler injection system. Clinical trials showed that 95% of patients found InnoLet 'very easy' or 'easy' to use.

InnoLet will be available in the US without prescription with both Novolin 70/30 (70% NPH & 30% Regular Human Insulin Injection [rDNA origin]) and Novolin N (NPH, Human Insulin Isophane Suspension [rDNA origin]), Novo Nordisk's premixed and long-acting human insulin formulations.